The emergence of positive data from trials like PATINA creates a dilemma for oncologists treating patients who are already stable on an older maintenance therapy. The consensus suggests not altering a successful regimen to avoid disrupting patient stability, revealing a cautious approach to integrating new evidence into established care.

The Destiny Breast 11 trial compared a new drug to a chemotherapy regimen (ACTHP) that many US oncologists no longer use. This choice of a less common control arm makes it difficult for them to directly compare the new treatment's efficacy against their own current standard (TCHP), complicating adoption.

Trials like CREST and Potomac show a consistent but modest event-free survival benefit when adding a PD-1 inhibitor to BCG for high-risk non-muscle-invasive bladder cancer. However, this comes with significant toxicity and no current overall survival benefit, creating a complex risk-benefit discussion for patients.

Dr. Patrick Baeuerle suggests that instead of engineering complex co-stimulatory signals into T-cell engagers, a more effective strategy is to combine them with standard-of-care treatments like chemotherapy or ADCs. This approach dramatically augments efficacy and has already prompted multiple Phase 3 trials.

The failure of the concurrent chemo-immuno-radiation approach has not stalled progress. Instead, new clinical trials are actively exploring novel strategies like SBRT boosts, dual checkpoint inhibitors, radiosensitizing nanoparticles, and induction immunotherapy to improve upon the current standard of care.

The POTOMAC trial's success adding durvalumab to BCG for non-muscle invasive bladder cancer introduces a major logistical hurdle. Urologists, who typically manage these patients, often lack the expertise to handle systemic immunotherapy side effects, creating uncertainty about which specialty will administer this new standard of care.

In the ASCENT-07 trial, investigators may have prematurely switched patients from the standard chemotherapy arm to superior, commercially available ADCs at the first hint of progression. This real-world practice can mask an experimental drug's true benefit on progression-free survival.

A significant criticism of the pivotal KEYNOTE-564 trial is that only half the patients in the control arm received standard-of-care immunotherapy upon relapse. This lack of subsequent optimal treatment complicates the interpretation of the overall survival benefit, raising questions about its true magnitude.

In high-risk non-muscle invasive bladder cancer (NMIBC), trials like CREST and POTOMAC show adding a systemic immune checkpoint inhibitor to BCG therapy introduces significant toxicity. The benefit is primarily in local control, which may not justify the risk, especially with other effective intravesical options available.